Jump to Navigation
Trends and Sentiments
Comments and Analysis
Jet Blue Wifi
Travel surviving long flights
FTSE falls as Trump fears send dollar lower
McDonald's earnings could be marred by wintry weather
We’re in the year of the biotech buyout, and here are...
The S&P 500 probably will rise this year, but it...
Suzlon gets 50.40 mw order for Gujarat wind power project
Ashoka University, IIMA to design an entrepreneurship...
Budget 2017 will save you taxes: SBI Research
Technology Leads Week With 5 IPO filings; 5 More Added To Calendar
8 U.S. IPOs Planned For The Week
IPO Preview: Cempra Holdings
2 Life Sciences IPOs Debut Below Target
Caesars Stands Out In A Busy IPO Week With Strong Returns
Trius Therapeutics: The Calm Before The Storm
2012 Biotech IPOs: Age Of The Dreamers?
2 Promising Biopharma Companies To Examine
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Companies That Can Mend The Biotech Market: Stephen Brozak
Cempra's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Cempra Management Discusses Toyama Exclusive Agreement Conference (Transcript)
Cempra's CEO Presents at BARDA Contract Award Conference (Transcript)
Can Cempra Beat The Superbugs?
Cempra's Platform Potentially Worth Billions In Battling Superbugs And MRSA
Cempra's CEO Discusses Q2 2013 Results - Earnings Call Transcript
Cempra's CEO Discusses Q3 2013 Results - Earnings Call Transcript
This Antibiotic Play May Be The Trius Of 2014
Cempra Holdings Hosts Solithromycin and Taksta Clinical Update Conference Call (Transcript)
Do Away With The Pill-A-Day Biotech Model: Steve Brozak
Cempra: Safety Results Solidifying Market Position
Cempra's CEO Discusses Q4 2013 Results - Earnings Call Transcript
Promising Biotechs Target New Ways To Kill Bad Bugs: Venture Capitalist Dennis Purcell
Cempra's CEO Discusses Q1 2014 Results - Earnings Call Transcript
Canada's Trudeau, Ministers to Discuss Trump...
The 10 things in advertising you need to know...
EUR/GBP: 1.1597 USD/EUR: 1.0744 JPY/USD: 113.4180
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions